COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #221 of 237
12/24 Late treatment study
Chari et al., Blood, doi:10.1182/blood.2020008150 (Peer Reviewed)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Source   PDF   Share   Tweet
Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjusted RR 0.67, p = 0.17 (data is in the supplementary material).

Chari et al., 12/24/2020, retrospective, multiple countries, multiple regions, peer-reviewed, median age 69.0, 25 authors.
risk of death, 33.1% lower, RR 0.67, p = 0.17, treatment 8 of 29 (27.6%), control 195 of 473 (41.2%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit